NSE · IPCALAB
IPCA Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,119 Cr with net profit ₹373 Cr — a 17.61% net margin, versus 11.62% the period before.
Shareholding
As of 2026-09-30
- Promoter44.72%
- Public7.15%
- FII11.53%
- DII36.59%
90,514 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.63× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #12 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,19,404 Cr | 33.19 | 5 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,12,658 Cr | 23.07 | 4.15 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,08,093 Cr | 30.2 | 3.14 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,442 Cr | 97.33 | 20.12 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹1,02,624 Cr | 31.85 | 2.68 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹91,390 Cr | 42.84 | 5.62 | 11.74% | 13.86% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 23.92 | 2.38 | 9.25% | 10.7% |
| Lupin Limited | ₹88,207 Cr | 14.81 | 3.92 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹61,147 Cr | 19.59 | 5.72 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹59,149 Cr | 25.96 | 4.26 | 16.66% | 14.31% |
| IPCA Laboratories Ltd.(this company) | ₹49,556 Cr | 36.09 | 6.14 | 14.15% | 12.94% |
AI analysis
AI-generated · google/gemini-2.5-flashIPCA Laboratories Ltd. is listed with a market capitalization of Rs 45641 Cr. The company reported a revenue growth of 16.02% and a profit margin of 11.83%.
Positives
- +The company's debt-to-equity ratio is 0.14, indicating a low level of leverage.
- +The dividend yield is 33%, providing a return to shareholders.
- +Return on capital employed is 18.5784%, indicating efficient use of capital.
- +Revenue grew 16.02%.
Negatives
- −The promoter holding has decreased from 46.0746% in June 2018 to 44.7243% in June 2026.
- −The price-to-earnings (PE) ratio is 135.16, which is relatively high.
Financial Performance
IPCA Laboratories Ltd. reported an annual revenue of Rs 9820.78 Cr for March 2026, with an EBITDA of Rs 1734.89 Cr and a net profit of Rs 1141.12 Cr for the same period. Quarterly revenue for March 2026 was Rs 2388.48 Cr, with a net profit of Rs 299.07 Cr. The company's profit margin stood at 11.83%.
Profitability & Returns
The company's return on equity (ROE) is 14.15%, and return on capital employed (ROCE) is 18.5784%. Earnings per share (EPS) for March 2026 were Rs 44.98, and the trailing EPS is Rs 46.52. The dividend yield is 33%.
Balance Sheet
IPCA Laboratories Ltd. has a book value per share of Rs 317.84. The debt-to-equity ratio is 0.14, indicating a low level of debt relative to equity. The company has a low debt-to-equity ratio of 0.14. No promoter pledges were reported for the period ending June 2026.
Ownership & Pledges
As of June 2026, promoter holding in IPCA Laboratories Ltd. was 44.7243%. Institutional holding, including DII and FII, was 48.0969%, with DIIs holding 37.3684% and FIIs holding 10.7285%. Public shareholders held 7.1788% of the company's shares. There were no promoter pledges reported for June 2026.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.